Compare ICL & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICL | IOVA |
|---|---|---|
| Founded | 1968 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 6.7B |
| IPO Year | 2001 | 2008 |
| Metric | ICL | IOVA |
|---|---|---|
| Price | $4.14 | $7.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $5.74 | ★ $14.50 |
| AVG Volume (30 Days) | 2.1M | ★ 12.8M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | ★ 4.72% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.83 | $58.86 |
| Revenue Next Year | $3.48 | $41.86 |
| P/E Ratio | $31.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.10 | $2.08 |
| 52 Week High | $6.97 | $15.37 |
| Indicator | ICL | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 25.23 | 31.10 |
| Support Level | N/A | $3.57 |
| Resistance Level | $5.79 | $9.36 |
| Average True Range (ATR) | 0.12 | 0.57 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 4.58 | 4.34 |
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates revenue from Brazil, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.